XML 16 R6.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 3 Months Ended 6 Months Ended 10 Months Ended 12 Months Ended
Dec. 31, 2016
Jun. 30, 2018
Jun. 30, 2017
Oct. 26, 2016
Dec. 31, 2017
Operating activities          
Net loss   $ (2,617,760) $ (2,023,899)    
Adjustments to reconcile net loss to net cash used in operating activities:          
Amortization   9,903 9,104    
Stock-based services expense   373,947 11,849    
Forgiveness of share subscription agreement for founders' shares   9,051    
Non-cash interest on short-term and convertible promissory notes   120,411 43,856    
Non-cash discount amortization on convertible and short-term promissory notes   377,026 482,505    
Note issuance costs attributed to warrant liability   38,119    
Revaluation of premium conversion derivatives   (351,616) 74,806    
Revaluation of warrant liability   16,025 (19,253)    
Loss on convertible notes and short-term notes extinguishment   186,220    
Change in assets and liabilities:          
Prepaid expenses   6,527 46,677    
Accounts payable and accrued expenses   584,458 414,019    
Net cash used in operating activities   (1,294,859) (913,166)    
Investing activities          
Purchase of intangible assets   (55,000)    
Net cash used in investing activities   (55,000)    
Financing activities          
Proceeds from issuance of convertible promissory notes   432,849 484,201    
Proceeds from issuance of warrants associated with short-term and convertible promissory notes   442,151 440,919    
Proceeds (repayment) from short-term unsecured loan   283,000 (50,000)    
Issuance costs related to convertible promissory notes   (33,039)    
Advances relating to long-term financing   188,000    
Issuance costs related to warrants   (29,570)    
Net cash provided by financing activities   1,346,000 812,511    
Net (decrease) increase in cash   (3,859) (100,655)    
Cash at beginning of period   26,467 522,217   $ 522,217
Cash at end of period $ 522,217 22,608 421,562   26,467
Supplemental non-cash financing and investing transactions:          
Bifurcation of premium conversion derivative related to convertible promissory notes   168,383 213,961    
Accrued issuance costs attributed to convertible promissory notes   2,850 39,781    
Accrued issuance costs attributed to warrant liability   38,119    
Common stock issued in connection with purchase of intangible assets   23,115    
NeuroOne LLC          
Operating activities          
Net loss       $ (18,604)  
Adjustments to reconcile net loss to net cash used in operating activities:          
Amortization       6,471  
Stock-based services expense        
Forgiveness of share subscription agreement for founders' shares        
Non-cash interest on convertible promissory notes        
Non-cash discount amortization on convertible and short-term promissory notes        
Note issuance costs attributed to warrant liability and to convertible promissory note modification        
Revaluation of premium conversion derivatives        
Revaluation of warrant liability        
Loss on convertible notes and short-term notes extinguishment        
Change in assets and liabilities:          
Prepaid expenses        
Accounts payable       186  
Accrued expenses       11,947  
Net cash used in operating activities        
Investing activities          
Purchase of intangible assets        
Net cash used in investing activities        
Financing activities          
Proceeds from issuance of convertible promissory notes and short-term notes        
Proceeds from issuance of warrants associated with short-term and convertible promissory notes        
Proceeds from issuance of warrants associated with short-term notes        
(Repayment) proceeds from short term unsecured loan        
Issuance costs related to short-term note        
Issuance costs related to convertible promissory notes        
Issuance costs related to warrants        
Net cash provided by financing activities        
Net (decrease) increase in cash        
Cash at beginning of period        
Cash at end of period        
Supplemental non-cash financing and investing transactions:          
Bifurcation of premium conversion derivative related to convertible promissory notes        
Issuance of additional warrants in connection with short-term notes modification        
Issuance of common stock for intangible assets        
Purchased intangible assets in accrued liabilities        
Accrued issuance costs attributed to convertible promissory notes        
Accrued issuance costs attributed to warrant liability        
Common stock issued in connection with purchase of intangible assets        
Successor          
Operating activities          
Net loss (266,370)       (5,058,426)
Adjustments to reconcile net loss to net cash used in operating activities:          
Amortization 1,269       17,633
Stock-based services expense       76,794
Forgiveness of share subscription agreement for founders' shares       9,050
Non-cash interest on convertible promissory notes 4,356       115,867
Non-cash discount amortization on convertible and short-term promissory notes 41,514       1,242,031
Note issuance costs attributed to warrant liability and to convertible promissory note modification 36,546       38,119
Revaluation of premium conversion derivatives 86       (17,962)
Revaluation of warrant liability 320       258,015
Loss on convertible notes and short-term notes extinguishment       350,914
Change in assets and liabilities:          
Prepaid expenses (53,823)       46,677
Accounts payable      
Accrued expenses 60,319       813,215
Net cash used in operating activities (175,783)       (2,108,073)
Investing activities          
Purchase of intangible assets       (91,709)
Net cash used in investing activities       (91,709)
Financing activities          
Proceeds from issuance of convertible promissory notes and short-term notes 354,360       1,004,134
Proceeds from issuance of warrants associated with short-term and convertible promissory notes 345,640       777,490
Proceeds from issuance of warrants associated with short-term notes       61,496
(Repayment) proceeds from short term unsecured loan 50,000       (50,000)
Issuance costs related to short-term note       (3,030)
Issuance costs related to convertible promissory notes (26,306)       (45,468)
Issuance costs related to warrants (25,694)       (40,590)
Net cash provided by financing activities 698,000       1,704,032
Net (decrease) increase in cash 522,217       (495,750)
Cash at beginning of period $ 26,467 $ 522,217   522,217
Cash at end of period 522,217       26,467
Supplemental non-cash financing and investing transactions:          
Bifurcation of premium conversion derivative related to convertible promissory notes 137,564       342,486
Issuance of additional warrants in connection with short-term notes modification       117,280
Issuance of common stock for intangible assets 150      
Purchased intangible assets in accrued liabilities 182,009       30,000
Accrued issuance costs attributed to convertible promissory notes 11,163       57,037
Accrued issuance costs attributed to warrant liability 10,852       38,119
Common stock issued in connection with purchase of intangible assets       $ 23,415